Can dacomitinib be used in combination?

Dacomitinib (Dacomitinib) can be used in combination with other medicines. The purpose of combined medication is to enhance the therapeutic effect or reduce the occurrence of drug resistance. In the treatment of non-small cell lung cancer (NSCLC), dacomitinib is often used in combination with other targeted drugs, chemotherapy drugs or immunotherapy. For exampleThe combination of osimertinib and dacomitinib can induce a more durable response by preventing the emergence of resistance. Existing data indicate that dacomitinib is effective in patients with NSCLC, both as initial therapy and after failure of first-generation inhibitors. Additionally, preclinical data indicate that dacomitinib can achieve responses in tumors harboring the T790M (gatekeeper mutation), which is present in up to 50% of tumors that are resistant to first-generation inhibitors.